Thomas C Rowe

Author:

Thomas D. Rowe

ISBN #:

0159004470

Author:

Thomas D. Rowe

ISBN #:

0159005043

Author:

Thomas D. Rowe

ISBN #:

0820546046

Author:

Thomas D. Rowe

ISBN #:

0820570419

Author:

Thomas Rowe

ISBN #:

0851053432

Author:

Thomas C. Rowe

ISBN #:

0789028077

Author:

Thomas C. Rowe

ISBN #:

0789028085

US Patent:

6627618, Sep 30, 2003

Filed:

Jan 5, 2001

Appl. No.:

09/755681

Inventors:

Volkmar Weissig - Allston MA
Jeffrey Allen Hughes - Gainesville FL
Jürgen Lasch - Halle, DE
Thomas Cardon Rowe - Gainesville FL

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K 4800

US Classification:

514 44, 4353201, 435455, 435458, 424450

Abstract:

The subject invention finds utility in the area of gene therapy of diseases. More specifically, the invention concerns the making of a novel non-viral vector which can bind to desired DNA to form a combination useful to transfect diseased mitochondria of human or animal cells. The non-viral vector comprises a dequalinium salt subjected to standard liposome production procedures to obtain the vector named DQAsomes.

US Patent:

8623854, Jan 7, 2014

Filed:

Jun 13, 2011

Appl. No.:

13/159016

Inventors:

Daniel M. Sullivan - Tampa FL, US
Joel G. Turner - Tampa FL, US
Thomas C. Rowe - Gainesville FL, US
David A. Ostrov - Gainesville FL, US

Assignee:

H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL
University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A01N 43/00
A61K 31/33
A01N 57/00
A61K 31/66
A01N 43/66
A61K 31/53
A01N 43/50
A61K 31/415

US Classification:

514183, 514124, 514244, 514245, 514401

Abstract:

A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase IIα and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo IIα have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.

US Patent:

61718637, Jan 9, 2001

Filed:

Sep 8, 1998

Appl. No.:

9/148953

Inventors:

Volkmar Weissig - Allston MA
Jeffrey Allen Hughes - Gainesville FL
Jurgen Lasch - Halle, DE
Thomas Cardon Rowe - Gainesville FL

Assignee:

University of Florida - Gainesville FL

International Classification:

C12N 1588

US Classification:

435458

Abstract:

The subject invention finds utility in the area of gene therapy of diseases. More specifically, the invention concerns the making of a novel non-viral vector which can bind to desired DNA to form a combination useful to transfect diseased mitochondria of human or animal cells. The non-viral vector comprises a dequalinium salt subjected to standard liposome production procedures to obtain the vector names DQAsomes.

US Patent:

60906197, Jul 18, 2000

Filed:

Sep 8, 1997

Appl. No.:

8/929175

Inventors:

Volkmar Weissig - Allston MA
Jeffrey Allen Hughes - Gainesville FL
Jurgen Lasch - Halle, DE
Thomas Cardon Rowe - Gainesville FL

Assignee:

University of Florida - Gainesville FL

International Classification:

C12N 1500
A61K 4800

US Classification:

4353201

Abstract:

The subject invention finds utility in the area of gene therapy of diseases. More specifically, the invention concerns the making of a novel non-viral vector which can bind to desired DNA to form a combination useful to transfect diseased mitochondria of human or animal cells. The non-viral vector comprises a dequalinium salt subjected to standard liposome production procedures to obtain the vector named DQAsomes.